Do analysts prefer HOWL or APVO?

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 919.02%. Given Werewolf Therapeutics' higher possible upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is HOWL or APVO more profitable?

Aptevo Therapeutics' return on equity of -198.50% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -208.23% -75.12% Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts rate NEUP or APVO?

Neuphoria Therapeutics presently has a consensus target price of $21.00, suggesting a potential upside of 536.36%. Given Neuphoria Therapeutics' higher possible upside, equities research analysts plainly believe Neuphoria Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Is NEUP or APVO more profitable?

Neuphoria Therapeutics' return on equity of -76.93% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neuphoria Therapeutics N/A -76.93% -54.76% Aptevo Therapeutics N/A -198.50% -117.06%

Which has better valuation and earnings, FTH or APVO?

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A

Is FTH or APVO more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -83.59% -256.50% Aptevo Therapeutics N/A -198.50% -117.06%

Do analysts prefer APVO or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, APVO or GTBP?

GT Biopharma is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is APVO or GTBP more profitable?

GT Biopharma's return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% GT Biopharma N/A N/A -102.03%

Do analysts prefer APVO or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is APVO or ALLR more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Allarity Therapeutics N/A -109.94% -47.27%

Aptevo Therapeutics (APVO) Competitors

$4.76 +0.02 (+0.42%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$4.43 -0.33 (-6.93%)

As of 07:49 AM Eastern

Compare

APVO vs. HOWL, NEUP, SNSE, GTBP, and ALLR

Should you buy Aptevo Therapeutics stock or one of its competitors? MarketBeat compares Aptevo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptevo Therapeutics include Werewolf Therapeutics (HOWL), Neuphoria Therapeutics (NEUP), Sensei Biotherapeutics (SNSE), GT Biopharma (GTBP), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry.

How does Aptevo Therapeutics compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Aptevo Therapeutics' return on equity of -198.50% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-208.23%	-75.12%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Aptevo Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	9.51	-$60.82M	-$1.24	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 919.02%. Given Werewolf Therapeutics' higher possible upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Werewolf Therapeutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Werewolf Therapeutics	Neutral
Aptevo Therapeutics	Neutral

Werewolf Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Summary

Werewolf Therapeutics beats Aptevo Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Neuphoria Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.14	-$370K	-$11.06	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

Neuphoria Therapeutics' return on equity of -76.93% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Neuphoria Therapeutics presently has a consensus target price of $21.00, suggesting a potential upside of 536.36%. Given Neuphoria Therapeutics' higher possible upside, equities research analysts plainly believe Neuphoria Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neuphoria Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

In the previous week, Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Aptevo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Aptevo Therapeutics	Neutral

Summary

Neuphoria Therapeutics beats Aptevo Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 5 mentions for Sensei Biotherapeutics and 0 mentions for Aptevo Therapeutics. Sensei Biotherapeutics' average media sentiment score of 0.20 beat Aptevo Therapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
Aptevo Therapeutics	Neutral

Sensei Biotherapeutics currently has a consensus target price of $54.00, suggesting a potential upside of 91.56%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sensei Biotherapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Sensei Biotherapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market. Comparatively, Aptevo Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A

Sensei Biotherapeutics' return on equity of -83.59% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-83.59%	-256.50%
Aptevo Therapeutics	N/A	-198.50%	-117.06%

Summary

Sensei Biotherapeutics beats Aptevo Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to GT Biopharma?

Aptevo Therapeutics (NASDAQ:APVO) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 1.2% of GT Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GT Biopharma is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GT Biopharma's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
GT Biopharma	N/A	N/A	-102.03%

Aptevo Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

In the previous week, Aptevo Therapeutics' average media sentiment score of 0.00 equaled GT Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Aptevo Therapeutics	Neutral
GT Biopharma	Neutral

Summary

Aptevo Therapeutics and GT Biopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Allarity Therapeutics' return on equity of -109.94% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Aptevo Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

In the previous week, Aptevo Therapeutics' average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aptevo Therapeutics	Neutral
Allarity Therapeutics	Neutral

Allarity Therapeutics has higher revenue and earnings than Aptevo Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Allarity Therapeutics	$320K	58.17	-$11.23M	-$0.72	N/A

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 776.07%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Allarity Therapeutics beats Aptevo Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APVO vs. The Competition

Export

Metric	Aptevo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.91M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.02	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.72	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.27	7.92	10.62	6.14
Net Income	-$25.97M	$23.81M	$3.60B	$331.74M
7 Day Performance	3.03%	-1.09%	-1.26%	-1.82%
1 Month Performance	1.93%	2.56%	1.07%	-1.45%
1 Year Performance	-91.33%	42.16%	23.63%	16.32%

Aptevo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APVO Aptevo Therapeutics	0.8546 of 5 stars	$4.76 +0.4%	N/A	-91.3%	$5.91M	N/A	N/A	50	Gap Up
HOWL Werewolf Therapeutics	3.0587 of 5 stars	$0.40 +6.5%	$3.75 +830.5%	-73.9%	$19.58M	$1.88M	N/A	40	Gap Down
NEUP Neuphoria Therapeutics	3.1981 of 5 stars	$3.54 +0.9%	$21.00 +493.2%	-55.7%	$19.13M	$15.65M	N/A	N/A
SNSE Sensei Biotherapeutics	N/A	$14.15 +2.1%	$48.00 +239.3%	N/A	$18.98M	N/A	N/A	40	Gap Up High Trading Volume
GTBP GT Biopharma	0.1577 of 5 stars	$0.43 -5.0%	N/A	-83.4%	$18.84M	N/A	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptevo Therapeutics (APVO) Competitors

APVO vs. HOWL, NEUP, SNSE, GTBP, and ALLR

How does Aptevo Therapeutics compare to Werewolf Therapeutics?

Summary

How does Aptevo Therapeutics compare to Neuphoria Therapeutics?

Summary

How does Aptevo Therapeutics compare to Sensei Biotherapeutics?

Summary

How does Aptevo Therapeutics compare to GT Biopharma?

Summary

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptevo Therapeutics (APVO) Competitors

APVO vs. HOWL, NEUP, SNSE, GTBP, and ALLR

How does Aptevo Therapeutics compare to Werewolf Therapeutics?

Is HOWL or APVO more profitable?

Which has stronger valuation & earnings, HOWL or APVO?

Do analysts prefer HOWL or APVO?

Do institutionals & insiders believe in HOWL or APVO?

Does the media prefer HOWL or APVO?

Which has more risk and volatility, HOWL or APVO?

Summary

How does Aptevo Therapeutics compare to Neuphoria Therapeutics?

Which has preferable valuation and earnings, NEUP or APVO?

Is NEUP or APVO more profitable?

Do analysts rate NEUP or APVO?

Do insiders & institutionals believe in NEUP or APVO?

Which has more risk and volatility, NEUP or APVO?

Does the media favor NEUP or APVO?

Summary

How does Aptevo Therapeutics compare to Sensei Biotherapeutics?

Do insiders & institutionals hold more shares of FTH or APVO?

Does the media favor FTH or APVO?

Do analysts prefer FTH or APVO?

Which has more volatility and risk, FTH or APVO?

Which has better valuation and earnings, FTH or APVO?

Is FTH or APVO more profitable?

Summary

How does Aptevo Therapeutics compare to GT Biopharma?

Do institutionals and insiders believe in APVO or GTBP?

Which has preferable valuation & earnings, APVO or GTBP?

Do analysts prefer APVO or GTBP?

Is APVO or GTBP more profitable?

Which has more risk & volatility, APVO or GTBP?

Does the media prefer APVO or GTBP?

Summary

How does Aptevo Therapeutics compare to Allarity Therapeutics?

Do institutionals and insiders believe in APVO or ALLR?

Is APVO or ALLR more profitable?

Which has more risk & volatility, APVO or ALLR?

Does the media prefer APVO or ALLR?

Which has preferable valuation & earnings, APVO or ALLR?

Do analysts prefer APVO or ALLR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APVO vs. The Competition

Aptevo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools